Diabetes, Disorder Related to Renal Transplantation
Conditions
Brief summary
Post-transplant diabetes affects 15 to 20% of renal transplant patients and contributes to increased morbidity and reduced survival of transplants and patients. Corticosteroids, anti-calcineurin and mammilian Target OF Rapamycin (mTOR) inhibitors have a major diabetogenic impact and greatly contribute to the increase in diabetes prevalence after transplantation. There are to date few studies concerning the pharmacological prevention of post-transplant diabetes. Hecking et al. have recently reported that a short treatment with insulin, administered immediately after transplantation, reduce the incidence of de novo diabetes one-year post-transplant. This study included 50 renal transplant patients and showed that a three months treatment of (Neutral Protamine Hagedorn) NPH insulin decreased HbA1c. The occurrence of diabetes, a secondary end-point, was reduced by 73% in the treated group. No further pharmacological strategy has been developed to date. Relevant experimental evidences suggest that gliptins could be used in the pharmacological prevention of post-transplant diabetes. These drugs are inhibitors of dipeptidyl peptidase-4 (DPP-4), which inactivates the incretins, the glucagon-like peptide-1 (GLP-1) and the gastric inhibitory polypeptide (GIP). DPP-4 inhibition causes an increase in the GLP-1 and GIP concentrations which induce insulin secretion and inhibition of glucagon secretion. The gliptins are approved for the treatment of type 2 diabetes. Beyond the effects on blood glucose, gliptins have pleiotropic effects including a protective effect on β cells and anti-inflammatory effect. The additional cost associated with new-onset diabetes after transplantation could be also significantly reduced by efficient prevention. A US study found that, for the period between 1994 and 1998, a newly diagnosed diabetic patient has cost $21,500 of medical expenses 2 years after transplantation. Moreover, transplantation resulting in one of the best increases of patients' quality of life, its estimate is essential in the treatment evaluation of this population.
Interventions
DRUGVildagliptin
Galvus is prescribed as recommended by the marketing authorization. In adults, the recommended dose of Galvus is 100 mg per day (one tablet in the morning and another in the evening). In patients with moderate or severe kidney problems, the recommended dose is 50 mg once daily (one tablet in the morning). Patients with creatinine clearance greater than 50 ml/min the vildalgliptin dose will be 100 mg/day. For those whose clearance is less than 50 ml/min, the daily dose is 50 mg. The creatinine clearance will be measured each week. The treatment duration will be 3 months, divided into 2 months of complete treatment and one month of cessation treatment with half dose of vildagliptin.
DRUGPlacebo
The placebo is the same as Galvus (packaging, shape, color, registration) but will contain only excipient. The given dose will also be identical.
Sponsors
University Hospital, Tours
University Hospital, Lille
Recherche Clinique Paris Descartes Necker Cochin Sainte Anne
Amiens University Hospital
University Hospital, Brest
Rennes University Hospital
Tenon Hospital, Paris
Centre Hospitalier Universitaire de Nice
University Hospital, Strasbourg, France
Centre Hospitalier Universitaire de Besancon
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Major Patients (18 year old or older) * Signature of informed consent * Affiliation to a French social security or receiving such a scheme * Patient receiving a first kidney transplant * Patients considered at high risk of developing posttransplant diabetes having at least 2 of the 3 following criteria: Age\> 50 years; BMI greater than 30 kg/m²; Direct Family history of type 2 diabetes * Patients who can receive immunosuppressive therapy including tacrolimus, mycophenolic acid and steroids * Patients in whom the cessation of steroids may be considered at the latest at Month 3 post-transplant
Exclusion criteria
* Legal disability or limited legal capacity * Topic unlikely to cooperate in the study and / or low early cooperation by the investigator * Patient without health insurance * Pregnancy * Patient in the period of exclusion of another study or under the national register of volunteers. * Inability to understand the reasons for the study; psychiatric disorders judged by the investigator to be incompatible with the inclusion in the study * Active infection * Infection with Hepatitis C virus * A history of diabetes * Multi-Organ Transplantation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diabetes event | 1 year | The primary endpoint is the proportion of diabetic patients 1 year after transplantation. Diabetic patients are defined as one of the following proposals: * Patients receiving a diabetic treatment * Patients have a fasting glucose above 7 mmol/l * Patients with an abnormal oral glucose tolerance test (OGTT) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Glycemic control | 3, 6 and 12 months | The criteria for secondary assessments are abnormal blood glucose measured by: the glycated hemoglobin (HbA1c) 3 months, 6 months and 12 months after transplantation. |
| Acute rejection, infections, graft and patient survival | 3, 6 and 12 months | The occurrence of acute rejection, infection, graft loss and patient death 3 months, 6 months and 12 months after transplantation. |
| The health-related quality of life improvement | 3, 6 and 12 months | The health-related quality of life (ReTRANSQOL questionnaire), 3 months, 6 months and 12 months after transplantation. |
| The cost-effectiveness ratio | 1 year | The cost-effectiveness of prevention of diabetes with vildagliptin |
Countries
France
Contacts
Primary ContactEmilie Gaiffe, Dr.
Backup ContactIngrid Tissot
Outcome results
None listed